Table 4.
Cumulative incidences and RRRs of micro- and macrovascular events over 30 years
| Cumulative incidence, % | Canagliflozin 300 mg | Dapagliflozin 10 mg | RRR |
|---|---|---|---|
| Macrovascular | |||
| MI | 19.1 | 19.4 | 1.5 |
| IHD | 18.1 | 18.3 | 1.0 |
| CHF | 12.0 | 12.1 | 1.0 |
| Stroke | 6.8 | 6.9 | 0.9 |
| PVD | 40.2 | 40.1 | – 0.1 |
| CHD (MI and IHD) | 33.1 | 33.5 | 1.2 |
| CVD (MI, IHD, and stroke) | 37.8 | 38.2 | 1.0 |
| Microvascular | |||
| Background diabetic retinopathy | 40.0 | 40.4 | 1.1 |
| Proliferative diabetic retinopathy | 1.6 | 1.6 | 2.1 |
| Macular edema | 23.4 | 23.8 | 1.6 |
| Blindness | |||
| One eye | 1.4 | 1.5 | 1.8 |
| Both eyes | 1.3 | 1.3 | 1.9 |
| Symptomatic neuropathy | 29.9 | 29.9 | 0.1 |
| Diabetic foot ulcer | 24.8 | 24.8 | 0.0 |
| Lower extremity amputation | 14.9 | 14.9 | 0.2 |
| Microalbuminuria | 10.4 | 10.5 | 0.9 |
| Macroalbuminuria | 6.9 | 6.9 | – 0.4 |
| CKD stage 3a | 35.5 | 35.4 | – 0.2 |
| CKD stage 3b | 23.3 | 23.2 | – 0.4 |
| CKD stage 4 | 14.5 | 14.5 | – 0.2 |
| CKD stage 5 | 7.8 | 7.7 | – 0.5 |
| ESRD | 6.7 | 6.7 | – 0.5 |
CHD coronary heart disease, CHF congestive heart failure, CKD chronic kidney disease, ESRD end-stage renal disease, IHD ischemic heart disease, MI myocardial infarction, PVD peripheral vascular disease, RRR relative risk reduction